Clinical Trials in Detroit

Showing 10821-10840 of 19,719 trials

Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units

NCT04829552

This is a multi-center, retrospective, study to determine if therapeutic dose anticoagulation (High dose group) improves inpatient mortality in severely ill patients with COVID-19 compared to prophylactic dose anticoagulation (Low dose group). The study involved 704 individuals who were admitted to Beaumont Health System (BHS) from March 10th to April 15th, 2020.

Covid19

Corewell Health East704 participantsStarted Mar 2020

Royal Oak, Michigan, United States

COMPLETEDPhase 313 miles

Essure (Model ESS310) Placement Rate Study

NCT02064413

To evaluate the safety and successful placement rate of Essure Model ESS310 device and any factors that may influence the successful placement rate of this device.

Contraception

Bayer134 participantsStarted Mar 2014

Glendale, Arizona, United States • Phoenix, Arizona, United States • Colorado Springs, Colorado, United States +13 more locations

TERMINATEDNA36 miles

Augmenting rTMS With Cognitive Control Training in Major Depressive Disorder

NCT04317495

Repetitive transcranial magnetic stimulation (rTMS) is an effective treatment for MDD, but the overall effect sized of the treatment is equivalent to antidepressant pharmacotherapy, and responses are highly variable. Given that rTMS is usually given to patients who have failed pharmacotherapy, a more effective alternative is needed. Therefore, this study will combine computerized cognitive training (CCT) during standard rTMS treatments and assess its feasibility, tolerability, and changes in cognitive control performance and depression symptoms. Participants that agree to the study and meet eligibility will receive standard rTMS (generally 25-36 daily treatments) along with CCT (starting on day 5 of treatment until the pre-taper treatment). In addition, to CCT participants will be asked to complete assessments before and after treatment

Major Depressive Disorder

University of Michigan4 participantsStarted Aug 2019

Ann Arbor, Michigan, United States

Prophylactic Versus Therapeutic Dose Anticoagulation In COVID-19 Infection at the Time of Admission To Critical Care Units

Essure (Model ESS310) Placement Rate Study

Augmenting rTMS With Cognitive Control Training in Major Depressive Disorder

Find Trials by Condition in Detroit

Rheos System for the Treatment of HFpEF Heart Failure

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Ultra-Low Tidal Volume Mechanical Ventilation in ARDS Through ECMO

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Peer Led Asthma Self Management for Adolescents: PLASMA

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC

Wide Frequency Band Test of Hearing in Veterans

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors